Pharvaris Officer/Director Schikan Files to Sell 200,000 Shares Worth $7M
PHVS sits 84% above its 52-week low of $20.65.
Summary
Pharvaris officer and director Johannes Schikan filed to sell 200,000 shares worth about $7 million, continuing a 90-day insider distribution pattern with no open-market buys.
Key Events · Ownership and Investor Activity · PHVS
-
Officer/Director Files to Sell 200,000 Shares
Johannes Gerardus Christiaan Petrus Schikan filed a Form 144 to sell 200,000 shares worth approximately $7.0 million, with a proposed sale date of 09/17/2026.
-
Continuing Insider Distribution Pattern
This is the 22nd Form 144 filing in 90 days; insider activity shows $11.2 million in net sales with no open-market buys.
-
Larger Than Concurrent Director Filing
The proposed sale is materially larger than the concurrent 52,500-share filing by Director Elisabeth Bjork worth about $1.99 million.
-
Recent Positive Phase 3 Data
The filing follows positive topline data from the CHAPTER-3 pivotal Phase 3 study of deucrictibant XR announced on 2026-09-08.
Analysis · PHVS · Life Sciences
Johannes Gerardus Christiaan Petrus Schikan, an officer and director of Pharvaris, filed a Form 144 to sell 200,000 shares worth approximately $7.0 million. This is the 22nd Form 144 filing in 90 days and continues a pattern of insider distribution with no open-market buys. The proposed sale is materially larger than the concurrent 52,500-share filing by Director Elisabeth Bjork, and it comes shortly after positive Phase 3 data for deucrictibant XR, suggesting insiders are monetizing gains following the stock's run-up.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.6% of the 1645 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PHVS was trading at $37.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $20.65 to $43.25. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.